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Abstract
Background: Hsp60, a Group I mitochondrial chaperonin, is classically considered an intracellular chaperone with residence
in the mitochondria; nonetheless, in the last few years it has been found extracellularly as well as in the cell membrane.
Important questions remain pertaining to extracellular Hsp60 such as how generalized is its occurrence outside cells, what
are its extracellular functions and the translocation mechanisms that transport the chaperone outside of the cell. These
questions are particularly relevant for cancer biology since it is believed that extracellular chaperones, like Hsp70, may play
an active role in tumor growth and dissemination.
Methodology/Principal Findings: Since cancer cells may undergo necrosis and apoptosis, it could be possible that
extracellular Hsps are chiefly the result of cell destruction but not the product of an active, physiological process. In this
work, we studied three tumor cells lines and found that they all release Hsp60 into the culture media by an active
mechanism independently of cell death. Biochemical analyses of one of the cell lines revealed that Hsp60 secretion was
significantly reduced, by inhibitors of exosomes and lipid rafts.
Conclusions/Significance: Our data suggest that Hsp60 release is the result of an active secretion mechanism and, since
extracellular release of the chaperone was demonstrated in all tumor cell lines investigated, our observations most likely
reflect a general physiological phenomenon, occurring in many tumors.
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Introduction
Human Hsp60, the product of the HSPD1 gene, is a Group I
mitochondrial chaperonin, phylogenetically related to bacterial
GroEL. Recently, the presence of Hsp60 outside the mitochondria
and outside the cell, e.g. in circulating blood, has been reported
[1,2]. Although it is assumed that Hsp60 extra-mitochondrial
molecule is identical to the mitochondrial one, this has not yet
been fully elucidated. Despite the increasing amount of experi-
mental evidences showing Hsp60 outside the cell, it is not yet clear
how general this process is and what are the mechanisms
responsible for Hsp60 translocation outside the cell. Neither of
these questions has been definitively answered, whereas there is
some information regarding extracellular Hsp70. This chaperone
was also classically regarded as an intracellular protein like Hsp60,
but in the last few years considerable evidences showed its
pericellular and extracellular residence [3,4]. Furthermore, it has
been reported that extracellular Hsp70 has a role in regulating
certain aspects of the immune response and in tumor growth and
dissemination [3]. Unfortunately, information on secretion of
Hsp60 by tumors is scarce in what concerns frequency of the
phenomenon, mechanism, and physiopathological role. Here, we
report results of experiments aimed at determining whether tumor
cells secrete Hsp60 and whether this is an active physiological
mechanism. Our data strongly suggest that extracellular Hsp60
release is the result of an active secretion mechanism not due to
cell damage or death with membrane disruption, probably
reflecting a general physiological phenomenon.
Results and Discussion
Tumor Cells Release Hsp60 and Hsp70 into the
Extracellular Culture Medium
Hsp60 and Hsp70 were detected in all samples, including
specific immunoprecipitates and exosomes purified from culture
media, and whole-cell lysates, obtained from the tumor cell lines
H292, A549 and K562 (see Materials and Methods).
Similar results were obtained with the non-tumor 16HBE cell
line with the exception of exosomes, which did not show detectable
levels of Hsp60 (Figure 1). Hsp70 was present in all tested
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exosomal samples from tumor and non-tumor cell lines,
confirming previous results and reaffirming the notion that this
Hsp is a reliable marker of exosomes [5]. The presence and quality
of exosomes in our preparations was further verified by
transmission electron microscopy (TEM), and by determining
acetylcholinesterase (AChE) activity and expression of Alix
protein.
A noteworthy finding from these experiments was that Hsp60
was detected in exosomes from all the tumor cell lines tested but
not in the exosomes of the non-tumor 16HBE cells, suggesting that
spontaneous release of this molecule usually occurs in tumor cells,
possibly reflecting their higher intracellular levels of Hsp60, which
might be due to overexpression of the hsp60 (HSPD1) gene and/or
other mechanisms such as increased translation rate and/or
increased mRNA or protein stability.
Exosome Characterization
The results shown in Figure 1 indicate that Hsp60 and Hsp70
were found in extracellular exosomes. To further ascertain the
identity of the exosomes obtained from the tumor and non-tumor
cells, exosomal preparations were examined by TEM and tested
for markers considered typical of exosomes.
a) Transmission electron microscopy of purified exo-
somes. Exosomes are vesicles of 30–90 nm in diameter that
originate in the endosomal system [6]. Figure 2A shows that the
exosomal preparations obtained presented the ultrastructural
hallmarks typical of exosomes.
b) Measurement of exosome-associated acetylcholin-
esterase activity. AChE activity is typically detected in
exosomes [7,8]. Consequently, experiments aimed at establishing
whether the exosomes purified from conditioned media showed
AChE activity were carried out. Results are displayed in Figure 2B.
The exosomes purified by ultra-centrifugation from culture media
of tumor and non-tumor cell lines showed AChE activity that
increased over the observation period of 30 min. In contrast, the
supernatants obtained after ultra-centrifugation showed very low
AChE activity in both cell lines throughout the observation period.
These results were a further confirmation of the presence of
exosomes in our extracellular samples.
c) Alix presence in extracellular exosomes and in the
intracellular counterparts. Alix is a protein that is widely
considered to be a valid marker of exosomes [9]; therefore, we
decided to investigate its presence in the exosomes purified from
the culture media. Figure 2C shows that this protein was indeed
present in our exosomal preparations and, as expected, in the
whole-cell lysates from tumor and non-tumor cell lines.
In conclusion, extracellular samples used in this study contained
exosomes, as confirmed by the typical ultrastructural features
observed with TEM, as well as by the presence of Hsp70 and Alix,
and AChE activity; moreover, exosomes from tumor cell lines
contained Hsp60 (Figure 1).
Figure 1. Extracellular release of Hsp60 and Hsp70 by tumor
cells. The two Hsps were found extracellularly in specific immunopre-
cipitates from conditioned media (a) and in exosomes purified from the
conditioned media from all three tumor cells tested (in A549, Hsp70
levels in immunoprecipitates from conditioned media were lower than
in the other cell lines) (b). Likewise, Hsp60 and Hsp70 were present in
immunoprecipitates from conditioned medium from the 16HBE non-
tumor cells. However, while Hsp70 was present in the exosomes
purified from the 16HBE conditioned medium, Hsp60 was not. As
expected, the two Hsps were present intracellularly in all cell lines, as
shown by the results with whole-cell lysates (c). Each set of four
Western Blot lanes represents four separate experiments. In conclusion,
the two Hsps were present intracellularly and were released into the
extracellular space by the tumor and non-tumor cells, but Hsp60 was
not secreted via exosomes by the non-tumor cells in contrast to Hsp70.
doi:10.1371/journal.pone.0009247.g001
Figure 2. Characterization of exosomes: Morphology, acetyl-
cholinesterase (AChE) activity, and Alix protein determina-
tions. Vesicles compatible with typical exosomes constituted our
exosomal preparations as demonstrated by TEM. An illustrative result
for exosomes purified from H292 cells is shown in A (bar 50 nm). B)
AChE activity in exosomal preparations from conditioned media and
supernatants obtained after ultra-centrifugation (sovra) from tumor
(H292) and non-tumor (16HBE) cells. Data are represented as mean 6
SD of AChE activity (AU) measured at 412 nm every 5 min for 30 min in
three independent experiments in duplicate. C) Demonstration of Alix
protein by Western blotting in: (a) four exosomal preparations (one for
each lane) from the conditioned media of the tumor cell line H292 and
the non-tumor cell line 16HBE in four separate experiments; and (b)
four whole-cell lysates from the same cell lines in four separate
experiments.
doi:10.1371/journal.pone.0009247.g002
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Mechanisms Responsible for Hsp60 Release into the
Extracellular Space
The data in the foregoing sections show that Hsp60 is found not
only inside cells but also in the extracellular culture medium of
tumor cell lines. We then proceeded to investigate whether the
presence of Hsp60 outside the cells is simply due to cell death and
membrane damage or to an active secretion mechanism in viable
cells.
a) Selection and calibration of protein-secretion
inhibitors. To begin dissecting the mechanisms involved in
the secretion of Hsp60 in the cell models used in this study and to
identify which protein-secretion machineries participate, we
resorted to inhibitors of well characterized protein traffic
pathways. This investigation was also fueled by our recent
finding that Hsp60 is increased in H292 cells, suggesting that it
is involved in tumor cell growth and cancer progression with a
potential role of extracellular chaperone in these processes [10].
Therefore, the following experiments were carried out on H292
cells, using DMA and MBC (see Materials and Methods) to inhibit
exosomes and lipid rafts, respectively.
In preparation for the inhibition tests, we measured (by MTT
and AnnexinV assays, see Materials and Methods) the effects on
viability/apoptosis of various doses and exposure times of DMA
and MBC in H292 cells (data not shown). Based on the results of
these preparatory experiments, non cytotoxic concentrations of the
inhibitors were subsequently used. MTT assay results indicated
that treatment of cells with DMA (5 nM) and MBC (1 mM)
for one hour was not cytotoxic (DMA: 94.95+/213.96% vs.
untreated control; MBC: 106.06+/210.25% vs. untreated control;
p = 0.39 and p = 0.17, respectively). AnnexinV assay confirmed
these results, since treatment with the inhibitors for one hour did
not significantly change viability levels (DMA: 91.33+/24.59%
and MBC: 90.79+/23.45% vs. untreated control: 89.7+/
23.89%; p = 0.43 and p = 0.52, respectively) and did not increase
the percentage of early apoptotic cells (DMA: 1.6+/20.3% and
MBC: 2.3+/20.7% vs. untreated control: 2.2+/20.5%; p = 0.59
and p = 0.79, respectively). In conclusion, treatment with the
inhibitors did not affect cell viability (necrosis and/or apoptosis) at
the doses used.
b) Hsp60 and Hsp70 secretion inhibition. Immunopre-
cipitates were prepared with conditioned media from inhibitor-
treated and untreated H292 cells, and tested as described under
Material and Methods. A marked decrease in Hsp60 secretion was
observed in cells treated with DMA (p,0.0001) or MBC
(p,0.0001) (Figure 3A, top panel). These data suggest that
exosomes and lipid rafts are actively involved in the release of
Hsp60 into the culture medium. As expected, Hsp70 secretion was
also considerably decreased after DMA (p,0.005) or MBC
(p,0.0001) treatment (Figure 3A, bottom panel); these results
are in accordance with those from other groups [11].
The findings reported in Figure 3A, indicate that the two Hsp
appear in the extracellular space due to an active mechanism, and
reinforce the hypothesis that lipid rafts may contribute to the
exosomal machinery [12,13]. Also of interest are the data from
whole-cell lysates showing that protein-secretion inhibitors had no
detectable effect on Hsp levels inside the cells (Fig. 3A, lanes b),
suggesting that the inhibitors used did not affect protein synthesis
and/or degradation. These data, together with what was observed
earlier in terms of cell viability, suggest that extracellular Hsp60
basal levels and their decrease following treatment with inhibitors,
could not have been influenced by dead cells or debris found in the
extracellular milieu, but rather were due to intracellular active
mechanisms and their alteration by the inhibitors.
Quantification of Extracellular Hsp60 in Conditioned
Media and Exosomes from H292 Tumor Cells before and
after Exposure to Protein-Secretion Inhibitors
In order to confirm the results described in the previous sections
by Western blotting, Hsp60 protein levels were quantified by ELISA
in conditioned media and exosomes from H292 cells. Conditioned
media and exosomes from H292 cells, untreated or treated with
DMA or MBC, were collected and processed as described under
Materials and Methods. Hsp60 levels in exosomes were 63.63% of
the total amount of this protein found in the conditioned media
(21.17 ng/mL/106 cells vs. 33.2 ng/mL/106 cells).
Treatment of H292 cells with the inhibitors (DMA or MBC)
caused a significant reduction of Hsp60 levels in the conditioned
media compared to untreated cells (p,0.001) (Figure 3Ba).
Likewise, Hsp60 levels measured in exosomes from inhibitor-
treated cells were significantly reduced compared to untreated
controls, as shown in Figure 3Bb (DMA p,0.0001 and MBC
p,0.001). In conclusion, the two different methods used, Western
blotting and quantitative ELISA, showed agreement in the data
obtained (Figures 3A and 3B), albeit with slightly different
sensitivity. Both methods clearly showed that in our model the
inhibitors decreased extracellular Hsp60 significantly, indicating
that chaperonin release into the extracellular space was due to active
mechanisms in which exosomes and lipid rafts were involved.
In order to demonstrate that DMA treatment specifically inhibited
exosomal secretion, AChE activity was measured in the exosomal
fractions after DMA treatment according to Savina et. al. [27].
Treatment of H292 cells with DMA, 5 nM for 1 hour, determined a
significant reduction in AChE activity compared to the untreated
control (0.095+/20.023 vs. 0.245+/20.148 OD, p,0.005).
To confirm the specificity of MBC treatment on lipid rafts
depletion, cellular cholesterol concentration in H292 cells treated
for 1 hour with MBC, 1 mM, was measured as described in the
Materials and Methods section. MBC treatment caused a 66%
reduction in cellular cholesterol content by comparison with the
untreated control.
Our observations relate to three tumor cell lines that were
selected for this study for specific reasons. H292 was used because its
levels of intracellular Hsp60 are high, suggesting a tendency for
extracellular release of this chaperone [10]. A549 was chosen
because of its similarities with H292 (both cell lines are very similar
cytomorphologically and, embryologically, the normal epithelium
from which they derive is the same, i.e., lower airways from the
primitive foregut), and we wanted to see whether what was observed
using one cell line could be reproduced in another comparable one.
Lastly, K562 was incorporated in our research because it is quite
distinct from the other two cell lines mentioned above, since it does
not represent a solid tumor, or epithelial cells, or cells from the
respiratory tract. We wanted to test if the observations made with
the other two cell lines could be repeated in a tumor cell line with
different origin and phenotype. Since all cell lines released Hsp60,
we hypothesize that our observations are likely to have general
validity and apply to a variety of tumors. This hypothesis is also
supported by other arguments, briefly discussed below.
Considerations and Conclusions
The role of extracellular Hsp60 in healthy and diseased tissue is
still unclear. Hsp60 has been found on the cell-membrane’s outer
surface in both normal [14] and tumor cells [15,16]. It has been
implicated in transmembrane transport and signaling [14,17],
activation and maturation of dendritic cells with generation of
antitumor T-cell responses [15,18], as well as in triggering
apoptosis [19]. Hsp60 may also be secreted from cells into the
Hsp60 Secretion by Tumor Cells
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interstitial fluid and thereby reach the bloodstream [20], where its
levels may be under genetic control [21]. In view of these data in
the literature, it is likely that the Hsp60 secretion reported in this
work is not an isolated phenomenon, a peculiarity of the cell lines
tested. On the contrary, all published information suggests that
Hsp60 secretion must occur often in vivo, in a variety of tumors and
situations, because this extracellular chaperone seems to be a part
of widespread intercellular communication events with profound
biologic effects. However, it remains to be determined where
circulating Hsp60 from tumor cells goes and what does it do at its
destination (or various destinations).
In regard to the secretion mechanisms for Hsp60 from tumor
cells, our studies contribute new data to an area still poorly
characterized. In the first place, we have shown that the presence
of Hsp60 in the extracellular media is not due to cell death and
destruction, but to an active secretion mechanism. Concerning the
latter mechanism, there is information indicating that Hsp70 is
secreted by normal and tumor cells via exosomes [4,22], but the
situation is less clear for Hsp60. Few years ago, it was reported that
exosomes obtained from a human B-lymphoblastoid cell line,
either before or after stress, did not contain Hsp60 [23]. In
contrast, other researchers have reported that exosomes derived
from a heat-shocked mouse B-cell lymphoma contained more
Hsp60 than the unstressed cellular counterparts [24]. More
recently, it was reported that Hsp60 is secreted by normal adult
rat cardiomyocytes through the exosomal pathway [20]. The part
played by lipid rafts in Hsp60 secretion by tumor cells is not
completely understood either. Lipid rafts are believed to be
involved in the process of exosome formation [12,13] and, in this
scenario, it is pertinent to mention that an association between
Hsp60 and lipid rafts of stressed endothelial cells has been
postulated [25]. Thus, it would be safe to assume that the results
obtained with a lipid raft inhibitor corroborate the data obtained
with an exosome inhibitor, since it is likely that both inhibitors hit
two different stages of the exosome pathway.
It is clear at the present time that Hsp60 in the cell membrane is
rare in normal cells but frequent in tumor cells [1,2]. The finding
that Hsp60 secretion is inhibited not only by DMA but also by
MBC, which is a lipid rafts inhibitor, supports the notion that this
chaperonin occurs in the cell membrane of tumor cells, although it
Figure 3. Effects of protein-secretion inhibitors on Hsp60 secretion by tumor cells. A) Hsp60 and Hsp70 detected by Western blotting in:
(a) immunoprecipitates from conditioned media from untreated (Unt) and inhibitor-treated H292 tumor cells; and (b) whole-cell lysates from H292
cells. The inhibitors are listed on top of the respective lanes. Histograms to the right represent the levels of the Hsps in immunoprecipitates
determined in three separate experiments as mean percentages +/2 SD of arbitrary units (AU) obtained with NIH image J 1.40 analysis software. *
and ** significantly different from untreated control, p,0.005 and p,0.001, respectively. The two inhibitors (listed below the bars) significantly
decreased secretion of Hsp60 and Hsp70. Also, the data from whole-cell lysates show that the protein-secretion inhibitors had no detectable effect on
Hsp levels inside the cells. B) Hsp60 levels secreted by the H292 tumor cells before and after exposure for 1 hour, followed by a 4 hours recovery
period, to protein-secretion inhibitors measured by ELISA in: (a) conditioned media; and (b) exosomes. Histograms represent Hsp60 levels expressed
as pg of protein normalized for mL normalised for 106 cells. Data represent mean +/2 SD of three different experiments in duplicate. * Significantly
different from untreated control, p,0.005. The results, which are in agreement with those obtained by Western blotting, show that the inhibitors
tested significantly reduced secretion of Hsp60 by the H292 tumor cells.
doi:10.1371/journal.pone.0009247.g003
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is not understood how Hsp60 reaches the cell membrane. We
hypothesize that the presence of Hsp60 in the cell membrane is
one of the key requirements for its secretion via the ‘‘lipid rafts-
exosomes’’ pathway. Also, it remains to be established why Hsp60
is released via exosomes by the tumor (i.e., H292) but is not by the
non-tumor (i.e., 16HBE) cells despite the fact that both are capable
of producing Hsp60 and exosomes.
Materials and Methods
Cell Cultures and Reagents
NCI-H292 (human mucoepidermoid bronchial carcinoma),
A549 (human lung adenocarcinoma) and K562 (human erythro-
leukemia) cell lines, referred to as ‘‘tumor cells’’ or ‘‘tumor cell
lines,’’ were obtained from the American Type Culture Collection
and maintained in RPMI 1640 with 10% heat-inactivated fetal
calf serum (FCS). We also used the SV40 large T antigen–
transformed 16HBE cell line, referred to as ‘‘non-tumor cells’’ or
‘‘non-tumor cell line,’’ a human bronchial epithelial cell line that
retains the differentiated morphology and function of normal
human airway epithelium [26]. The 16HBE cells were cultured in
Dulbecco-modified Eagle’s medium with 10% FCS and supple-
mented with 2 mM glutamine, 50 U/ml penicillin, and 50 mg/
streptomycin. All cell lines, except K562, were grown as
monolayers attached to the culture vessel and cultured at 37uC,
5% CO2 in a humidified incubator. Passage number of cells used
in this study ranged from 12 to 35. Unless otherwise stated, cell
culture reagents were purchased from GIBCO BRL LIFE
Technologies (Invitrogen, Italy). Prior to all the experiments,
confluent cell monolayers were incubated in serum–free medium
(to avoid possible contaminations by bovine exosomes from the
FCS) for the indicated times.
Protein-Secretion Inhibitors
5,5-(N-N-Dimetyl)-amiloride hydrochloride (DMA), an exoso-
mal inhibitor [27], and methyl-b-cyclodextrin (MBC), a lipid-raft
pathway inhibitor - since it depletes cellular cholesterol and
disrupts lipid rafts [11] - were purchased from Sigma (Italy).
Antibodies
Anti-Hsp60 (clone LK1) monoclonal antibody was purchased
from Sigma and used diluted 1:1,000; anti-Hsp70 (clone W27)
monoclonal antibody was purchased from Santa Cruz Biotech-
nologies (CA, USA) and used diluted 1:1,000; Anti-Alix mono-
clonal antibody was purchased from Pharmingen (BD Biosciences,
CA, USA) and used diluted 1:500. Control mouse immunoglob-
ulins with isotypes matching those of the anti-Hsp antibodies were
purchased from Sigma, and used before immunoprecipitation with
the anti-Hsp antibodies to remove proteins from the media that
bind immunoglobulins non-specifically [28]. Horseradish peroxi-
dase (HRP)-conjugated sheep anti-mouse antibody and Protein-A
Sepharose were purchased from Amersham Biosciences (Ge
Healthcare, Italy).
Preparation of Extracellular Fractions from Cell Cultures
Exposed to Protein-Secretion Inhibitors and Untreated
Controls
a) Conditioned medium. Eighty ml of conditioned medium
from 70–806106 cells was collected after 24 hrs of culture in
serum-free medium, and centrifuged (8006g for 10 min) to
eliminate cells and debris that might have been present. Thirty
ml of this medium was then dialyzed in a buffer of 50 mM NaCl
plus 0.05% Nonidet at 4uC O/N, subsequently lyophilized and
stored at 4uC, and resuspended just before use into a solution
containing RIPA buffer (25 mM Hepes, 300 mM NaCl, 150 mM
MgCl, 0.2 mM EDTA, 1% Triton X, 0.25% deoxycholate, 0.05%
SDS and protease inhibitors cocktail; Roche, Italy). Five hundred
mg of proteins in this resuspended solution (representing the
conditioned medium in toto, referred to as ‘‘conditioned medium’’)
was used for immunoprecipitation and, in turn, the immuno-
precipitate (referred to as ‘‘immunoprecipitate’’ as described later,
under Immunoprecipitation) was used for Western blotting to
quantify Hsp. Fifty ml of the remaining resuspended solution
(conditioned medium) was not immunoprecipitated, but used for
exosome isolation as described below.
b) Exosomes purification. Exosomes were isolated
according to a previously published method [27]. Briefly, 50 ml
of cell- and debris-free conditioned medium (see above, (a)
Conditioned medium) was collected on ice and centrifuged at
13,0006g for 20 min to bring down and eliminate small cellular
debris and mitochondrial contaminants that might have been
present. The supernatant was collected and exosomes were
separated from it by centrifugation at 110,0006g for 2 hrs in a
Beckman 60 Ti rotor; the pellet (exosomal fraction) was saved and
washed once in phosphate-buffered saline (PBS), resuspended in
100 ml of PBS containing protease inhibitors, and stored at 280uC
until use; supernatants after ultra-centrifugation were stored at
280uC and used for AChE activity determination.
c) Exosomes validation by Transmission Electron
Microscopy (TEM). Exosome pellets purified from all cell lines
studied were examined by TEM to ascertain the presence of exosomal
vesicles. Pellets were resuspended in residual fluid from a PBS wash,
followed by addition of 100 ml ice-cold, freshly made fixative (2.5%
glutaraldeyde in PBS) to preserve vesicle structure and morphology.
Preparations were mounted on formvar nickel 300-mesh grids by
layering grids over 10-ml drops of exosome preparations for 10 min
at room temperature. Grid-mounted preparations were stained with
uranyl acetate and lead citrate, and subsequently examined with a
Jeol (JEM 1220) TEM at 120 kV.
d) Exosomes validation by acetylcholine esterase assay
and protein Alix determination. The presence of exosomes
was confirmed by measuring the activity of acetylcholineesterase
(AChE), an enzyme that is considered a marker for these vesicles [7]
and by measuring the protein Alix, which is also considered a
marker of exosomes [9]. Briefly, for the AChE assay, 15 ml of the
exosomal preparation was suspended in 100 ml of PBS and
incubated with acetylthiocholine (1.25 mM) and 5,59-dithio-bis-(2-
nitrobenzoic acid) (0.1 mM) in a final volume of 1 ml. The
incubation was carried out in cuvettes at 37uC and the change in
absorbance at 412 nm was monitored every 5 minutes for 30
minutes. For Alix detection, we used Western blotting with a specific
antibody (see section Antibodies). Acetylthiocholine iodide and
5,59-dithio-bis-(2-nitrobenzoic acid) were purchased from Sigma.
Intracellular Proteins: Whole-Cell Lysate Preparations
from Cell Cultures Treated with Protein-Secretion
Inhibitors and Untreated Controls
Treated and untreated cells were lysed into ice-cold lysis
solution containing RIPA buffer, as previously described [28].
Lysates were then spun at 16,0006g for 30 min at 4uC, the
supernatant was recovered, its protein concentration determined,
and then stored at 280uC until use. This preparation is referred to
as ‘‘whole-cell lysate.’’
Protein Quantification
Proteins were quantified in conditioned media and corresponding
immunoprecipitates - see following section -, exosomal prepara-
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tions, as well as in whole-cell lysates from inhibitor-treated and
untreated control cultures with the Quant-iTTM protein assay kit
(Invitrogen Molecular Probes, Italy), using the Qubit fluorometer
according to the manufacturer’s instructions (the kit is accurate for
protein concentrations ranging from 12.5 mg/ml to 5 mg/ml).
Immunoprecipitation
To assess the presence and quantify Hsp60 in the ‘‘conditioned
medium’’ (namely, the resuspended lyophilized powder described
above under Preparation of extracellular fractions. a)
Conditioned medium), 500 mg protein was incubated with
3 mg of anti-Hsp60 antibody at 24uC for 2 h, followed by
incubation with 20 ml protein-A Sepharose at 4uC for 12 h.
Subsequently, the incubation mixture was centrifuged in a
microcentrifuge at 14,0006g for 30 sec at 4uC, the pellet was
collected and resuspended in lysis buffer and centrifuged again:
this procedure was repeated three times. The last pellet was
solubilized by boiling into 2x sample buffer (2% SDS, 10%
glycerol, 100 mM DTT, 60 mM Tris-HCl [pH 6.8] and 0.001%
bromophenol blue), and used for SDS-PAGE as described under
Western blotting. The final immunoprecipitate preparation is
referred to as ‘‘conditioned medium Hsp60-immunoprecipitate.’’
The same protocol, using anti-Hsp70 instead of the anti-Hsp60
antibody, was applied to assess Hsp70; the final preparation
obtained is referred to as ‘‘conditioned medium Hsp70-immuno-
precipitate.’’ All immunoprecipitates were tested by Western
blotting.
Western Blotting
Western blotting analyses of immunoprecipitates, exosomes,
and whole-cell lysates were performed as previously described
[28]. Briefly, 40 mg of proteins from immunoprecipitates or whole-
cell lysates, or 25 ml of exosomes (protein concentrations ranging
from 0.45 to 1 mg/ml) was added to 4x Laemmli buffer and heated
for 5 min at 95uC. Proteins were resolved by 12% SDS-PAGE
along with a molecular weight marker (Bio-RAD laboratories,
Italy). Proteins were then transferred to nitrocellulose membranes.
After transfer, all membranes were stained with Poinceau S to
verify the quality of transfer and loading similarity. Before
applying antibodies, the membranes were blocked with 5% fat
milk, and probed for 12 hours with the specific antibody, followed
by incubation with horseradish peroxidase-conjugated second
antibody. Blots were detected using the Supersignal West Femto,
according to the manufacturer’s instructions (Pierce, Italy), and
chemiluminescent signals were recorded with the ChemiDoc XRS
imager (Bio-RAD Laboratories). Densitometric analysis of blots
was performed using the NIH Image J 1.40 analysis program
(National Institutes of Health, Bethesda, MD, USA).
Treatment with Inhibitors
Cells were seeded in serum free medium under the same
conditions described previously and treated with 5 nM DMA or
1 mM MBC for 1 hour, followed by 4 hours recovery period.
Extracellular medium was processed as described before and was
used for immunoprecipitation and for purification of exosomes.
MTT Assay to Assess Cell Viability
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide] was obtained from Sigma (Italy), and the assay was performed
as described [29]. Briefly, 56103 H292 cells were plated in 200 ml of
complete (with FCS) medium per well in 96-well plates. After
24 hrs, complete medium was replaced with FCS-free medium, and
the protein secretion inhibitor DMA (at 30, 15, 7, and 5 nM), or
MBC (at 5, and 1 mM) was added for one hour. The medium
containing the inhibitor was replaced, the cells were left to recover
in inhibitor-free medium for 4 hours and, at the end of this
incubation period, MTT was dissolved in fresh medium and added
to the cell cultures at a final concentration of 0.5 mg/ml. Following
a 4-hour incubation period, cells were solubilized in 200 ml DMSO/
well and optical density (OD) was measured with a plate reader
(Titertek Multiskan MCC/340, Flow Laboratories, Switzerland) at
570 nm (630 nm as reference). Cell viability was expressed as the
percentage of the OD value of inhibitor-treated cells compared with
untreated controls, according to the following equation: Viabili-
ty = (OD SAMPLE/OD CONTROL)6100. Each experiment was
carried out in duplicate and a total of three experiments were
performed for each inhibitor.
Early Apoptosis Determination
Fifty thousand H292 cells/well were plated into 24-well plates
and grown until 80% confluence. Growth medium was replaced
with FCS-free medium for 24 hours and cells were then treated with
protein-secretion inhibitor DMA (5 nM) or MBC (1 mM) for one
hour, followed by a 4-hour recovery period in inhibitor-free
medium. These times and doses were chosen according to the MTT
assay results as described in the Results section. H292 cells were
then harvested for early apoptosis analysis according to a previously
published technique [30], in which binding of Annexin V (AxV) is
used to detect phosphatidylserine that is externalized on the outer
leaflet of the plasma membrane of apoptotic cells. AxV-FITC
(1 mg/ml) and propidium iodide (PI, 2.5 mg/ml) were added to
tubes containing 16105 cells/100 ml binding buffer. Cells were
incubated in the dark for 15 min, and then analyzed using a
FACScan flow cytometer (Becton Dickinson, Oxford, UK). Control
tubes lacking either AxV-FITC or PI, or both, were included to
complete the controls. Analysis of dot-plots of fluorescence detector
(FL) 1 (AxV-FITC) versus FL2 (PI) was performed using Win MDI
2.8 (Flow cytometry software, University of Massachusetts, MA,
USA). The degree of early apoptosis was expressed as the number of
AxV+/PI- cells shown as the percentage of total cells. Each
experiment was carried out in duplicate and a total of three
experiments were performed.
Cholesterol Depletion
To deplete cellular cholesterol, cells were treated with MBC as
describe above. The cell pellets were collected, lysed, and the
intracellular cholesterol concentrations were determined using the
pertinent Roche Kit according to the manufacturer’s instructions
(Roche, Milan, Italy).
ELISA
Quantitative comparisons of Hsp60 levels in conditioned media
and exosomes by ELISA were performed using a commercial
Hsp60 EIA Kit from Stressgen Assay Designs Inc (Ann Arbor, MI,
USA). The results obtained with this assay were normalized for
cell number and expressed as pg\mL\106 cells.
Statistical Analysis
Data are presented as the mean 6 SD of triplicate
determinations. Comparisons between groups were performed
using the unpaired samples Student’s t test. A p value#0.05 was
considered statistically significant.
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